Engineers have developed a new process of 3D bioprinting tissues that uses multiple cell-based inks to create more realistic structures in less time than previous methods.
Scientists and bioengineers are warming up to cryogenic electron microscopy (cryo-EM), an ultra-low-temperature technique for visualizing the atomic-level inner workings of human cells and other applications.
Gain access to free tools and resources from AABME, an initiative designed to stimulate biomedical innovation by bringing together and providing resources to the biomedical engineering community.
It’s no secret that most biomedical firms today use modeling to make research and development decisions. What remains to be seen is how to take modeling, within companies and among regulatory agencies, to the next level.
Medical device makers lag other industries in their use of computer models. One of the big issues discussed at AABME CONNECT is how much can researchers, regulators, and engineers trust their models and simulation?
Columbia University researchers recently generated beating cardiac tissue from induced pluripotent stem cells, human cells that are able to differentiate into nearly any cell type. Using physical conditioning, the researchers produced samples with the hallmarks of mature heart tissue with just four weeks of cell culture. The work paves a concrete pathway to functional heart-on-a-chip platforms.
Biomedical engineers at Texas A&M University developed a hydrogel made from nanoflakes of synthetic clay and sugar chains extracted from seaweed. The gel could act as an injectable bandage to stop internal bleeding on a battlefield, in a surgical suite, or at an accident site.
Lorenzo Moroni and his team at University of Maastricht's Institute for Technology-Inspired Regenerative Medicine (MERLN) in The Netherlands, use 3D bioprinting to create "smart scaffolds," which they seed with patient stem cells and growth factors to produce structures that behave like natural cartilage tissues.
Cellular Biomedicine Group, a clinical-stage biopharmaceutical company that develops immunotherapies for cancer and stem cell therapies for degenerative diseases, recently partnered with GE Healthcare to build a platform to produce therapies at scale for clinical trials. Aims to solve challenge of developing enough genetically modified cells to test products on large populations.
Bioengineer, entrepreneur, MIT grad, designer Wen Wang invented an athletic-wear fabric that uses bacteria-activated vents to cool down the wearer.
Joseph Wu Director of the Stanford Cardiovascular Institute and Professor of Medicine and Radiology at Stanford University, discusses the rise of engineered cell and tissue products for use in patients. While these products are now technically advanced and better suited for the clinic, there continues to be issues around patient safety that need to be monitored and mitigated for routine use and mass production.
A new nuclease inhibitor drug program could lead to the commercialization of novel DNA damage response (DDR) treatments for female breast, ovarian, and other types of cancers.
Researchers use minibioreactor arrays to study the gut, coupling them with high-throughput screening techniques to examine the effects of different therapies on digestive system diseases. Reported by AABME.org
Rice University researchers have found that breaking down a virus’s tough outer shell creates nanoparticles that could improve the delivery of chemotherapies and other medicines to diseased cells.
This “skin on a chip” bioreactor can help researchers study and treat keloid disease and other forms of extreme scarring.